TSC Ratings provides exclusive stock, ETF and mutual fund recommendations using proprietary tools. Our "safety first" approach aims to reduce risk while achieving total return performance.BOSTON ( TheStreet) -- The following fast-growth companies are projected to increase revenue and profit by at least 12% in the coming year and receive "buy" ratings from our proprietary quantitative model, which considers more than 60 factors. They are ordered by their potential to appreciate. Teva Pharmaceuticals ( TEVA) is an Israeli company that develops and markets a range of generic and branded pharmaceuticals, biogenerics and active pharmaceutical ingredients. The numbers: First-quarter revenue increased 22% to $3.1 billion as net income surged 225% to $451 million and earnings per share climbed 183% to 51 cents. The operating margin declined to 18% and the net margin increased to 14%. The company has conservative leverage, as reflected by a debt-to-equity ratio of 0.5. But a quick ratio of 0.8 indicates a less-than-ideal liquidity position. The stock: Teva is up 18% in 2009, outperforming the Dow Jones Industrial Average and the S&P 500. The stock trades at a price-to-earnings ratio of 48, indicating a significant premium to its peers, and offers a modest 1.2% dividend yield. National Presto Industries ( NPK) makes small appliances, and defense and absorbent products. The numbers: First-quarter revenue increased 40% to $108 million as earnings ascended 74% to $11 million, or $1.58 per share. The operating margin improved to 14% and the net margin climbed to 10%. National Presto has no debt or interest expenses and abundant cash reserves, as reflected by a quick ratio of 3.6. The stock: National Presto is down 1% in 2009, underperforming the Dow and S&P 500. The stock trades at a price-to-earnings ratio of 11 and offers an attractive 6% dividend yield.